LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on activators of free fatty acid receptors (GPR120) implicated in the development of…
Epidarex co-founder and managing partner Kyp Sirinakis has joined TEDCO’s new Task Force for Women Entrepreneurs. The task force is dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland. Click here to view the full press release.
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Lucia Celona as Chief People Officer. Prior to…
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, today announced its plans to develop APL-9 for the prevention of complement immune…
Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the…
Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as Independent Director Cambridge, UK, Boston and Seattle – April 10th, 2019 – NodThera, a biotechnology company developing a new class…
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining…
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory…
Epidarex Capital, a leading early stage life science firm, is delighted to announce the addition of two veteran life science professionals to its transatlantic team. Dr. Henning Steinhagen has joined as a Venture Partner and will support Epidarex in building exciting life science companies around…
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat…